日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)

诱导化疗(西妥昔单抗、紫杉醇和卡铂)后,再进行放化疗(西妥昔单抗、紫杉醇和卡铂)治疗 III/IV 期头颈部鳞状细胞癌:一项 II 期 ECOG-ACRIN 试验 (E2303)

Wanebo, H J; Lee, J; Burtness, B A; Ridge, J A; Ghebremichael, M; Spencer, S A; Psyrri, D; Pectasides, E; Rimm, D; Rosen, F R; Hancock, M R; Tolba, K A; Forastiere, A A

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer

骨桥蛋白和活化白细胞粘附分子的组合作为 HER2 和 ER 阴性乳腺癌的强效预后鉴别因素

M Ihnen, R M Wirtz, K T Kalogeras, K Milde-Langosch, M Schmidt, I Witzel, A G Eleftheraki, C Papadimitriou, F Jänicke, E Briassoulis, D Pectasides, A Rody, G Fountzilas, V Müller